Deal Watch: Esperion Augments Cardiovascular Franchise Via Corstasis Buyout
Plus deals involving Ono/Congruence, RallyBio/Candid, Gyre/Cullgen, Pfizer/Sciwind, Swiss Rockets/Complete Genomics, GSK/Frontier, Harbour/Solstice, Angelini/Quiver and more.
Scrip - March 3, 2026

Small, Mid-Cap Companies Plot European Expansion In The Age Of MFN
A new wave of commercial-stage biopharmas are interested in launching drugs in Europe but weighing risks related to US drug pricing policies
Scrip - March 3, 2026

Priovant’s Brepocitinib May Launch Sooner Than Expected
The US FDA gave priority review to the JAK1/TYK2 inhibitor, moving the Roivant company’s potential launch date from early 2027 to September 2026.
Scrip - March 3, 2026

Companies Reconsider Selling Ex-US Rights Due To MFN Drug Pricing Policy
At BIO’s Investor and Growth Summit, panelists said biopharma companies that in the past would have out-licensed ex-US rights to their drugs are scrapping those plans due to most favored nation pricing in the US.
Scrip - March 3, 2026

Pfizer CEO On FDA Vaccines Decisions: ‘We Have A Problem With CBER Leadership’
Albert Bourla has once again been outspoken in his criticism of Vinay Prasad’s attempts to overrule FDA staff approval recommendations for vaccines, but he was more positive about other US policy reforms.
Scrip - March 3, 2026

Nutromics Targets Vancomycin’s Dosing Blind Spot With Continuous Drug-Monitoring Patch
Nutromics’ wearable microneedle patch seeks to provide continuous drug monitoring in acute care patients starting with the hard-to-dose antibiotic vancomycin.
Medtech Insight - March 3, 2026

CMS Fraud Crackdown, Part 2: Agency Seeking Stakeholder Feedback To Help ‘CRUSH’ Medicare Fraud
CMS is asking stakeholders to help the agency craft potential regulatory changes aimed at bolstering its efforts to combat Medicare and Medicaid fraud. The agency has provided several topics to help guide stakeholder engagement.
Medtech Insight - March 3, 2026

RadNet’s $270M Gleamer Buy Takes Aim At GE HealthCare’s AI Ambitions
RadNet's CEO Berger sees little overlap with GE's Intelerad deal, which he argues is a PACS viewer – not a true AI rival. DeepHealth, he believes, has the potential to transform the radiology workflow.
Medtech Insight - March 3, 2026

Beiersdorf ‘Rebalancing’ Nivea As Global Skin Market Weakness, China Reset, Dampen Brand Sales
German company Beiersdorf AG has launched an initiative to strategically “rebalance” its Nivea skin care brand to return it to an ‘elevated growth trajectory.’
HBW Insight - March 4, 2026

Meet The New Boss, Same As The Old Boss: Hikma Sticks With Darwazah As CEO
Following the departure of Hikma’s former CEO Riad Mishlawi at the end of last year, the company’s chair Said Darwazah has once again taken on the chief executive role for the next two years, amid a slew of other management changes.
Generics Bulletin - March 3, 2026

‘The Pirates All Know Where The Treasure Is’ – Staying Ahead Of The Competition In US Biosimilars
At the AAM’s Access! 2026 conference, a dedicated panel on the latest developments for biosimilars discussed challenges and opportunities in the US market, predicting consolidation among current players as well as calling for policies that put biosimilars first.
Generics Bulletin - March 3, 2026

Natco, Breckenridge Confirm US Pomalidomide Entry With Shared Exclusivity
Natco and US partner Breckenridge have launched generic pomalidomide in the US, targeting a $3.2bn market. The firms believe they have 180 days of shared exclusivity, strengthening Natco’s oncology portfolio.
Generics Bulletin - March 3, 2026

Fresenius Kabi Bets On Volume Growth To Drive 2026 Margin Expansion
Kabi targets mid- to high-single-digit growth and a 16.5%-17% EBIT margin in 2026, raising its long-term ambition as it pivots toward biopharma and innovation – while warning margin gains hinge on volume ramp and operating leverage.
Generics Bulletin - March 3, 2026

Headlamp Health’s Lumos AI Targets Cause Of CNS Trial Failure
Headlamp Health's Lumos AI uses a ‘neurosymbolic’ multi-agent framework to improve CNS trial patient selection, targeting the heterogeneity that drives neuroscience's high attrition rate.
In Vivo - March 3, 2026

Praxis Eyes Blockbuster Future As Precision Neurology Pipeline Matures
Praxis Precision Medicines is planning to shift from a clinical-stage company to a competitive commercial player in CNS, with the potential to launch multiple blockbuster medicines in the near future.
In Vivo - March 3, 2026